您的当前位置:首页 > Focus > 【adoucisseur d'eau co2】Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance 正文
时间:2024-09-29 12:29:16 来源:网络整理 编辑:Focus
SAN FRANCISCO, CA / ACCESSWIRE / January 2, 2019 /Jaguar Health, Inc. (JAGX) ("Jaguar" or the "Compa adoucisseur d'eau co2
SAN FRANCISCO,adoucisseur d'eau co2 CA / ACCESSWIRE / January 2, 2019 /
Jaguar Health, Inc. (
JAGX
) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that Company management will host a conference call on Monday, January 7, 2019 at 8 a.m. Eastern Time to discuss 4Q'18 performance.
Dial-In Instructions for Conference Call
When:
January 7, 2019 at 8 a.m. Eastern Time
Dial-in (US Toll Free):
800-289-0438
Dial-in (International):
323-794-2423
Conference ID number:
3695186
Live webcast on the investor relations section of Jaguar's website (
click here
)
Replay Instructions
Dial-in (US Toll Free):
844-512-2921
Dial-in (International):
412-317-6671
Conference ID number:
3695186
Replay of the webcast on the investor relations section of Jaguar's website (
click here
)
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi
®
(crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
For more information about Jaguar, please visit
jaguar.health
. For more information about Napo, visit
napopharma.com
.
About Mytesi
®
Mytesi
®
(crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi
®
is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi
®
. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at
Mytesi.com
. Crofelemer, the active ingredient in Mytesi
®
, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal
Croton lechleri
tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Story continues
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will host a conference call on January 7, 2019. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
Jaguar-JAGX
SOURCE:
Jaguar Health, Inc.
View comments
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates2024-09-29 11:59
Before You Buy Youngevity International, Inc. (NASDAQ:YGYI), Consider Its Volatility2024-09-29 11:39
Facebook warned it may lose a key seal of approval for ad measurement - WSJ2024-09-29 11:25
Global watchdog warns over financial staff curbs in pandemic2024-09-29 10:41
ICE wants to use facial recognition to track people threatening its agents online2024-09-29 10:28
Key Things To Understand About Peyto Exploration & Development's (TSE:PEY) CEO Pay Cheque2024-09-29 10:02
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates2024-09-29 09:54
Live Oak Acquisition Corp. II Announces Pricing of Upsized $220,000,000 Initial Public Offering2024-09-29 09:48
Voya: 3Q Earnings Snapshot2024-09-29 12:01
NYSE: REZI Shareholder Notice: Lawsuit against Resideo Technologies, Inc. announced by Shareholders Foundation2024-09-29 11:47
Don't Let China Control Your Networks, U.S. Envoy Tells Europe2024-09-29 11:39
General Electric Stock Falls 3%2024-09-29 11:34
Were Hedge Funds Right About Mostly Avoiding Marsh & McLennan Companies, Inc. (MMC)?2024-09-29 11:14
The Zacks Analyst Blog Highlights: Telenav, Forestar, Alpine Income Property Trust, Innovative Industrial Properties and MDU Resources2024-09-29 10:50
Callon Petroleum Climbs 4% As 3Q Sales Surge 74%; Street Sticks To Hold2024-09-29 10:39
Westland Insurance Acquires Diamond Insurance Agencies in Alberta2024-09-29 09:58
Retail sector companies turn to masks, gloves in coronavirus fight2024-09-29 09:49